|
1
|
Strategies for multivessel revascularization in patients with diabetes.
|
N Engl J Med
|
2012
|
10.79
|
|
2
|
Bivalirudin during primary PCI in acute myocardial infarction.
|
N Engl J Med
|
2008
|
5.86
|
|
3
|
A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation.
|
J Am Coll Cardiol
|
2004
|
5.67
|
|
4
|
Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis.
|
J Am Coll Cardiol
|
2004
|
3.67
|
|
5
|
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
|
Lancet
|
2013
|
3.17
|
|
6
|
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.
|
Lancet
|
2011
|
3.00
|
|
7
|
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials.
|
J Am Coll Cardiol
|
2008
|
2.54
|
|
8
|
Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.
|
J Am Coll Cardiol
|
2011
|
2.49
|
|
9
|
The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
|
J Invasive Cardiol
|
2010
|
2.10
|
|
10
|
Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.
|
J Am Coll Cardiol
|
2011
|
2.05
|
|
11
|
Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction.
|
J Am Coll Cardiol
|
2002
|
1.95
|
|
12
|
Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention.
|
J Invasive Cardiol
|
2003
|
1.77
|
|
13
|
Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study.
|
J Am Coll Cardiol
|
2005
|
1.73
|
|
14
|
Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.
|
N Engl J Med
|
2009
|
1.72
|
|
15
|
Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis.
|
Circulation
|
2004
|
1.72
|
|
16
|
Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
|
J Am Coll Cardiol
|
2011
|
1.72
|
|
17
|
Coronary artery aneurysms after drug-eluting stent implantation.
|
JACC Cardiovasc Interv
|
2008
|
1.70
|
|
18
|
Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study.
|
J Am Coll Cardiol
|
2003
|
1.62
|
|
19
|
Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions.
|
J Am Coll Cardiol
|
2004
|
1.61
|
|
20
|
Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I.
|
Circulation
|
2005
|
1.60
|
|
21
|
Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions.
|
Kidney Int
|
2005
|
1.57
|
|
22
|
An evaluation of fluoroscopy time and correlation with outcomes after percutaneous coronary intervention.
|
J Invasive Cardiol
|
2007
|
1.46
|
|
23
|
Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II.
|
Circulation
|
2005
|
1.46
|
|
24
|
Female gender and mortality after percutaneous coronary intervention: results from a large registry.
|
Catheter Cardiovasc Interv
|
2011
|
1.45
|
|
25
|
Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry.
|
Catheter Cardiovasc Interv
|
2009
|
1.44
|
|
26
|
Restenosis due to underexpansion of sirolimus-eluting stent in a bifurcation lesion.
|
Catheter Cardiovasc Interv
|
2003
|
1.42
|
|
27
|
The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study.
|
Catheter Cardiovasc Interv
|
2013
|
1.40
|
|
28
|
Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents.
|
Catheter Cardiovasc Interv
|
2008
|
1.39
|
|
29
|
Comparison of safety and efficacy between first and second generation of angio-seal closure devices in interventional patients.
|
J Invasive Cardiol
|
2004
|
1.39
|
|
30
|
Acute angiographic and clinical results of the NIR w/SOX stent.
|
J Invasive Cardiol
|
2002
|
1.39
|
|
31
|
Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach.
|
Eur Heart J
|
2007
|
1.37
|
|
32
|
Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial.
|
J Am Coll Cardiol
|
2011
|
1.23
|
|
33
|
Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis.
|
J Am Coll Cardiol
|
2009
|
1.22
|
|
34
|
Intravascular ultrasound classification of plaque distribution in left main coronary artery bifurcations: where is the plaque really located?
|
Circ Cardiovasc Interv
|
2010
|
1.19
|
|
35
|
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
|
Am Heart J
|
2004
|
1.19
|
|
36
|
Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials.
|
J Am Coll Cardiol
|
2006
|
1.17
|
|
37
|
Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes.
|
Circulation
|
2003
|
1.16
|
|
38
|
Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes.
|
JACC Cardiovasc Imaging
|
2012
|
1.14
|
|
39
|
Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure.
|
Catheter Cardiovasc Interv
|
2002
|
1.12
|
|
40
|
Percutaneous recanalization of chronically occluded coronary arteries: procedural techniques, devices, and results.
|
Catheter Cardiovasc Interv
|
2005
|
1.12
|
|
41
|
Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial.
|
Am Heart J
|
2008
|
1.11
|
|
42
|
Intravascular ultrasound study of patterns of calcium in ruptured coronary plaques.
|
Am J Cardiol
|
2005
|
1.09
|
|
43
|
Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial).
|
Am J Cardiol
|
2010
|
1.04
|
|
44
|
Inverse relationship between body mass index and coronary artery calcification in patients with clinically significant coronary lesions.
|
Atherosclerosis
|
2011
|
1.03
|
|
45
|
Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis.
|
Clin J Am Soc Nephrol
|
2009
|
1.03
|
|
46
|
Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.
|
Am Heart J
|
2011
|
1.03
|
|
47
|
Transplantation of autologous endothelial cells induces angiogenesis.
|
Pacing Clin Electrophysiol
|
2003
|
1.00
|
|
48
|
Prevalence and prediction of previously unrecognized peripheral arterial disease in patients with coronary artery disease: the Peripheral Arterial Disease in Interventional Patients Study.
|
Catheter Cardiovasc Interv
|
2009
|
0.99
|
|
49
|
Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.
|
J Am Coll Cardiol
|
2002
|
0.98
|
|
50
|
Necrotic core and its ratio to dense calcium are predictors of high-risk non-ST-elevation acute coronary syndrome.
|
Am J Cardiol
|
2007
|
0.97
|
|
51
|
Successful use of the frontrunner catheter in the treatment of in-stent coronary chronic total occlusions.
|
Catheter Cardiovasc Interv
|
2004
|
0.97
|
|
52
|
Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention.
|
Am J Cardiol
|
2008
|
0.96
|
|
53
|
Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions.
|
Am J Cardiol
|
2004
|
0.95
|
|
54
|
Commentary: New insights into the risk factors of contrast-induced encephalopathy.
|
J Endovasc Ther
|
2011
|
0.95
|
|
55
|
Contrast-induced nephropathy.
|
Catheter Cardiovasc Interv
|
2008
|
0.95
|
|
56
|
Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function.
|
Rev Cardiovasc Med
|
2003
|
0.94
|
|
57
|
5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial.
|
JACC Cardiovasc Interv
|
2011
|
0.94
|
|
58
|
Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy).
|
J Am Coll Cardiol
|
2013
|
0.93
|
|
59
|
Impact of major bleeding and blood transfusions after cardiac surgery: analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial.
|
Am Heart J
|
2012
|
0.91
|
|
60
|
Incidence and angiographic characteristics of patients with apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONS-AMI trial: an analysis from a multicenter, international study of ST-elevation myocardial infarction.
|
Catheter Cardiovasc Interv
|
2013
|
0.90
|
|
61
|
Vascular closure devices: a review of their use after invasive procedures.
|
Am J Cardiovasc Drugs
|
2005
|
0.90
|
|
62
|
Intravascular ultrasonic assessment of stent diameters derived from manufacturer's compliance charts.
|
Am J Cardiol
|
2005
|
0.89
|
|
63
|
Thrombosis after implantation of drug-eluting stents.
|
Hellenic J Cardiol
|
2006
|
0.88
|
|
64
|
Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: analysis from the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction trial.
|
Circulation
|
2011
|
0.88
|
|
65
|
Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon.
|
Am J Cardiol
|
2007
|
0.87
|
|
66
|
The predictive value and evolution of N-terminal pro-B-type natriuretic peptide levels following transcutaneous aortic valve implantation.
|
J Interv Cardiol
|
2011
|
0.87
|
|
67
|
Novel site-specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in a porcine coronary restenosis model.
|
Catheter Cardiovasc Interv
|
2005
|
0.87
|
|
68
|
The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale.
|
Am Heart J
|
2008
|
0.87
|
|
69
|
Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial.
|
Circ Cardiovasc Interv
|
2011
|
0.86
|
|
70
|
Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation.
|
J Am Coll Cardiol
|
2002
|
0.86
|
|
71
|
Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial.
|
EuroIntervention
|
2011
|
0.86
|
|
72
|
Drug-eluting stents in the real world: how intravascular ultrasound can improve clinical outcome.
|
Am J Cardiol
|
2008
|
0.86
|
|
73
|
Comparison of differences in outcome after percutaneous coronary intervention in men versus women <40 years of age.
|
Am J Cardiol
|
2004
|
0.85
|
|
74
|
Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era.
|
Am J Cardiol
|
2007
|
0.85
|
|
75
|
Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators).
|
Am J Cardiol
|
2010
|
0.84
|
|
76
|
Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial).
|
Am J Cardiol
|
2005
|
0.84
|
|
77
|
Cardiovascular magnetic resonance imaging evaluation of two families with Becker muscular dystrophy.
|
Neuromuscul Disord
|
2010
|
0.84
|
|
78
|
Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial.
|
Am Heart J
|
2012
|
0.83
|
|
79
|
Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model.
|
J Am Coll Cardiol
|
2002
|
0.83
|
|
80
|
Humanized mouse model of thrombosis is predictive of the clinical efficacy of antiplatelet agents.
|
Circulation
|
2011
|
0.83
|
|
81
|
Fibrinolytic activity and bleeding after cardiac surgery with cardiopulmonary bypass and low-dose aprotinin therapy.
|
Blood Coagul Fibrinolysis
|
2003
|
0.83
|
|
82
|
B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial.
|
Circ Cardiovasc Interv
|
2012
|
0.82
|
|
83
|
Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound.
|
Am J Cardiol
|
2006
|
0.82
|
|
84
|
Comparison of in-hospital and one-year outcomes after multiple coronary arterial stenting in patients > or =80 years old versus those <80 years old.
|
Am J Cardiol
|
2003
|
0.82
|
|
85
|
Late stent thrombosis: the last remaining obstacle in coronary interventional therapy.
|
Curr Cardiol Rep
|
2012
|
0.81
|
|
86
|
Update on In-stent Restenosis.
|
Curr Interv Cardiol Rep
|
2001
|
0.81
|
|
87
|
Percutaneous mitral valve repair: lessons from the EVEREST II (Endovascular Valve Edge-to-Edge REpair Study) and beyond.
|
JACC Cardiovasc Interv
|
2011
|
0.81
|
|
88
|
How serious a problem is bleeding in patients with acute coronary syndromes?
|
Curr Cardiol Rep
|
2011
|
0.81
|
|
89
|
Comparison of outcomes in men versus women having percutaneous coronary interventions in small coronary arteries.
|
Am J Cardiol
|
2003
|
0.81
|
|
90
|
Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III).
|
Am J Cardiol
|
2003
|
0.81
|
|
91
|
Correlation of coronary arterial remodeling determined by intravascular ultrasound with angiographic diameter reduction of 20% to 60%.
|
Am J Cardiol
|
2003
|
0.80
|
|
92
|
The Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry.
|
Am Heart J
|
2012
|
0.80
|
|
93
|
Comparison of one-year outcomes after percutaneous coronary intervention among current smokers, ex-smokers, and nonsmokers.
|
Am J Cardiol
|
2002
|
0.80
|
|
94
|
Deferoxamine enhances neovascularization and recovery of ischemic skeletal muscle in an experimental sheep model.
|
Ann Thorac Surg
|
2003
|
0.80
|
|
95
|
Comparison of clinical outcomes using stents versus no stents after percutaneous coronary intervention for proximal left anterior descending versus proximal right and left circumflex coronary arteries.
|
Am J Cardiol
|
2002
|
0.80
|
|
96
|
Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial).
|
Am J Cardiol
|
2011
|
0.80
|
|
97
|
Antegrade, retrograde, and combination strategies for chronic total occlusions.
|
Curr Cardiol Rep
|
2010
|
0.80
|
|
98
|
Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors.
|
Am J Cardiol
|
2002
|
0.80
|
|
99
|
Optimal final lumen area and predictors of target lesion revascularization after stent implantation in small coronary arteries.
|
Am J Cardiol
|
2003
|
0.80
|
|
100
|
How to diagnose, how to treat: renal artery stenosis-diagnosis and management.
|
J Clin Hypertens (Greenwich)
|
2002
|
0.80
|
|
101
|
Minimally invasive direct coronary artery bypass (MIDCAB) versus coronary artery stenting for elective revascularization of the left anterior descending artery.
|
Am J Cardiol
|
2002
|
0.79
|
|
102
|
A Comparison of Tirofiban and Abciximab in Patients Undergoing Coronary Stent Implantation: Rationale, Design, and Results of the TARGET Trial.
|
Curr Interv Cardiol Rep
|
2001
|
0.79
|
|
103
|
Patients with 3-vessel coronary artery disease and impaired ventricular function undergoing PCI with Impella 2.5 hemodynamic support have improved 90-day outcomes compared to intra-aortic balloon pump: a sub-study of the PROTECT II trial.
|
J Interv Cardiol
|
2015
|
0.79
|
|
104
|
Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy.
|
J Thromb Thrombolysis
|
2011
|
0.79
|
|
105
|
Intravascular ultrasound assessment of fibrous cap remnants after coronary plaque rupture.
|
Am Heart J
|
2006
|
0.79
|
|
106
|
Comparison of surgical pericardial drainage with percutaneous catheter drainage for pericardial effusion.
|
J Invasive Cardiol
|
2012
|
0.79
|
|
107
|
Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis.
|
Am J Cardiol
|
2003
|
0.78
|
|
108
|
Bifurcation stenting with drug-eluting stents: a systematic review and meta-analysis of randomised trials.
|
EuroIntervention
|
2009
|
0.78
|
|
109
|
Facilitated/pharmaco-invasive approaches in STEMI.
|
Curr Cardiol Rev
|
2012
|
0.78
|
|
110
|
Association among leukocyte count, mortality, and bleeding in patients with non-ST-segment elevation acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] trial).
|
Am J Cardiol
|
2013
|
0.78
|
|
111
|
Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model.
|
Cardiovasc Radiat Med
|
2004
|
0.78
|
|
112
|
Contrast-induced acute kidney injury. Underappreciated or a new marker of cardiovascular mortality?
|
J Am Coll Cardiol
|
2010
|
0.78
|
|
113
|
Evolution of intravascular assessment of coronary anatomy and physiology: from ultrasound imaging to optical and flow assessment.
|
Eur J Clin Invest
|
2013
|
0.78
|
|
114
|
Revascularization strategies for stable multivessel and unprotected left main coronary artery disease: from BARI to SYNTAX.
|
Int J Cardiol
|
2011
|
0.78
|
|
115
|
Vascular remodeling and plaque composition between focal and diffuse coronary lesions assessed by intravascular ultrasound.
|
Am J Cardiol
|
2004
|
0.78
|
|
116
|
Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model.
|
Cardiovasc Radiat Med
|
2002
|
0.78
|
|
117
|
Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial.
|
Expert Rev Cardiovasc Ther
|
2012
|
0.78
|
|
118
|
Percutaneous recanalization of chronic total occlusions: wherein lies the body of proof?
|
Am Heart J
|
2012
|
0.78
|
|
119
|
Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions.
|
J Am Coll Cardiol
|
2003
|
0.77
|
|
120
|
Comparison of six risk scores in patients with triple vessel coronary artery disease undergoing PCI: competing factors influence mortality, myocardial infarction, and target lesion revascularization.
|
Catheter Cardiovasc Interv
|
2013
|
0.77
|
|
121
|
Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model.
|
Catheter Cardiovasc Interv
|
2004
|
0.77
|
|
122
|
Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).
|
Am J Cardiol
|
2005
|
0.77
|
|
123
|
First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial.
|
JACC Cardiovasc Interv
|
2009
|
0.77
|
|
124
|
Usefulness of atrial fibrillation as a marker of outcome after percutaneous coronary intervention.
|
Am J Cardiol
|
2003
|
0.77
|
|
125
|
Relation between the degree of procedural anticoagulation and complications after coronary stent implantation.
|
Am J Cardiol
|
2003
|
0.77
|
|
126
|
Leukocyte count is a modulating factor for the mortality benefit of bivalirudin in ST-segment-elevation acute myocardial infarction: the HORIZONS-AMI trial.
|
Circ Cardiovasc Interv
|
2013
|
0.77
|
|
127
|
Creatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque.
|
Am J Cardiol
|
2005
|
0.77
|
|
128
|
Revascularization of unprotected left main coronary artery disease: strategy selection and systematic risk assessment.
|
Catheter Cardiovasc Interv
|
2012
|
0.77
|
|
129
|
Role of PLA2 polymorphism on clinical events after percutaneous coronary intervention.
|
Acute Card Care
|
2009
|
0.76
|
|
130
|
Systemic hypothermia to prevent radiocontrast nephropathy (from the COOL-RCN Randomized Trial).
|
Am J Cardiol
|
2011
|
0.76
|
|
131
|
Dominant contribution of negative remodeling to development of significant coronary bifurcation narrowing.
|
Am J Cardiol
|
2003
|
0.76
|
|
132
|
Study of atheromatous plaque using intravascular ultrasound.
|
Hellenic J Cardiol
|
2008
|
0.76
|
|
133
|
Percutaneous revascularization of left main: role of imaging, techniques, and adjunct pharmacology.
|
Catheter Cardiovasc Interv
|
2012
|
0.76
|
|
134
|
Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes.
|
J Thromb Thrombolysis
|
2007
|
0.76
|
|
135
|
Cerebral Embolic Protection During TAVR: A Clinical Event Meta-Analysis.
|
J Am Coll Cardiol
|
2017
|
0.76
|
|
136
|
Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection.
|
J Am Coll Cardiol
|
2003
|
0.76
|
|
137
|
Editorial commentary: in-stent restenosis and cutting balloon.
|
J Invasive Cardiol
|
2002
|
0.75
|
|
138
|
Angiographic complications and post-PCI myocardial enzyme elevation: brave new world revisited.
|
Catheter Cardiovasc Interv
|
2010
|
0.75
|
|
139
|
Clinical investigation in ACS and PCI: shooting in the dark at a moving target.
|
Catheter Cardiovasc Interv
|
2009
|
0.75
|
|
140
|
Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome.
|
Am J Cardiol
|
2004
|
0.75
|
|
141
|
To excel or to confirm? That is the question.
|
Catheter Cardiovasc Interv
|
2011
|
0.75
|
|
142
|
Clopidogrel loading dose pre-PCI: how high?
|
J Invasive Cardiol
|
2004
|
0.75
|
|
143
|
Editorial comment--Hypotension after carotid revascularization.
|
Stroke
|
2003
|
0.75
|
|
144
|
Interventional therapy for acute myocardial infarction: respect the microvasculature.
|
J Am Coll Cardiol
|
2003
|
0.75
|
|
145
|
Percutaneous Coronary Intervention Outcomes in Very Elderly Patients From a Single Large-Volume Tertiary Care Center, Specifically Focusing on Nonagenarians.
|
JACC Cardiovasc Interv
|
2017
|
0.75
|
|
146
|
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
|
Hosp Pract (1995)
|
2010
|
0.75
|
|
147
|
Transcatheter aortic valve implantation: lessons from the PARTNER (Placement of Aortic Transcatheter Valves) trial.
|
JACC Cardiovasc Interv
|
2011
|
0.75
|
|
148
|
Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
|
EuroIntervention
|
2014
|
0.75
|
|
149
|
Multivessel disease: percutaneous coronary intervention for classic coronary artery bypass grafting indications.
|
Angiology
|
2008
|
0.75
|
|
150
|
Effects of baseline and early acquired thrombocytopaenia on long-term mortality in patients undergoing percutaneous coronary intervention with bivalirudin.
|
EuroIntervention
|
2016
|
0.75
|
|
151
|
Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents.
|
J Invasive Cardiol
|
2014
|
0.75
|
|
152
|
New-device angioplasty in women: clinical outcome and predictors in a 7,372-patient registry.
|
Epidemiology
|
2002
|
0.75
|
|
153
|
Prognostic Significance of Cardiac Amyloidosis in Patients With Aortic Stenosis: A Systematic Review and Meta-Analysis.
|
JACC Cardiovasc Imaging
|
2020
|
0.75
|
|
154
|
Coronary artery spasm associated with a moderately severe atherosclerotic stenosis in the proximal LAD.
|
J Invasive Cardiol
|
2002
|
0.75
|
|
155
|
Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction.
|
Catheter Cardiovasc Interv
|
2012
|
0.75
|
|
156
|
The optimal pharmacological formula for percutaneous coronary intervention.
|
Expert Opin Pharmacother
|
2011
|
0.75
|
|
157
|
Normal to normal: a method of treatment of coronary aneurysms with deployment of bare-metal stents.
|
J Invasive Cardiol
|
2011
|
0.75
|
|
158
|
Acute and long-term outcomes of cutting balloon angioplasty followed by gamma brachytherapy for in-stent restenosis.
|
Am J Cardiol
|
2003
|
0.75
|
|
159
|
Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes.
|
Catheter Cardiovasc Interv
|
2004
|
0.75
|
|
160
|
Optimal catchment area and primary PCI centre volume revisited: a single-centre experience in transition from high-volume centre to "mega centre" for patients with ST-segment elevation myocardial infarction.
|
EuroIntervention
|
2015
|
0.75
|
|
161
|
Can manual thrombus aspiration improve myocardial reperfusion?
|
Nat Clin Pract Cardiovasc Med
|
2006
|
0.75
|
|
162
|
Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients >or=75 years of age versus those <75 years of age.
|
Am J Cardiol
|
2003
|
0.75
|
|
163
|
Treatment of restenotic drug-eluting stents: an intravascular ultrasound analysis.
|
J Invasive Cardiol
|
2007
|
0.75
|
|
164
|
Comparison of frequency of hemorrhagic stroke in patients <75 years versus > or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions.
|
Am J Cardiol
|
2004
|
0.75
|
|
165
|
Physiological correlates of densely calcified coronary lesions on coronary computed tomography angiography among patients with low-to-intermediate coronary artery disease likelihood.
|
Coron Artery Dis
|
2011
|
0.75
|
|
166
|
Is accurate intravascular ultrasound evaluation of the left circumflex ostium from a left anterior descending to left main pullback possible?
|
Am J Cardiol
|
2010
|
0.75
|
|
167
|
Premature coronary artery disease in systemic lupus erythematosus with extensive reocclusion following coronary artery bypass surgery.
|
J Invasive Cardiol
|
2003
|
0.75
|
|
168
|
Favorable effect of gamma-radiation for in-stent restenosis: effect of diabetes on angiographic and clinical outcomes.
|
Catheter Cardiovasc Interv
|
2004
|
0.75
|
|
169
|
Usefulness of the angiographic pattern of in-stent restenosis in predicting the success of gamma vascular brachytherapy.
|
Am J Cardiol
|
2003
|
0.75
|
|
170
|
Coronary artery stenting.
|
Catheter Cardiovasc Interv
|
2002
|
0.75
|